- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
SAB Biotherapeutics to Report Q4 2025 Earnings
The biotech company will release its latest financial results on Friday, March 27.
Mar. 20, 2026 at 5:03am
Got story updates? Submit your updates here. ›
SAB Biotherapeutics (NASDAQ:SABS) is scheduled to report its fourth-quarter 2025 financial results before the market opens on Friday, March 27. Analysts expect the company to post earnings of ($0.16) per share for the quarter.
Why it matters
SAB Biotherapeutics is a clinical-stage biotech company focused on developing polyclonal antibody therapies. Investors will be closely watching the company's latest earnings report for signs of progress in its pipeline and financial performance.
The details
SAB Biotherapeutics will host a conference call to discuss the Q4 2025 results on Monday, March 9, 2026 at 7:00 AM ET. The company reported a loss of ($0.46) per share in the previous quarter, missing analysts' consensus estimate of ($0.16) per share.
- SAB Biotherapeutics will release its Q4 2025 earnings on Friday, March 27, 2026.
- The company will host a conference call to discuss the results on Monday, March 9, 2026 at 7:00 AM ET.
The players
SAB Biotherapeutics
A clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota that focuses on developing fully human polyclonal antibody therapeutics.
What’s next
Investors will be watching to see if SAB Biotherapeutics can meet or exceed analysts' expectations when the company reports its Q4 2025 results on March 27.
The takeaway
SAB Biotherapeutics' upcoming earnings report will provide insight into the company's financial performance and progress in its pipeline of polyclonal antibody therapies, which could be of interest to investors in the biotech sector.
